Sharon Graw
Concepts (310)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 22 | 2026 | 358 | 2.590 |
Why?
| | Arrhythmias, Cardiac | 11 | 2026 | 352 | 0.950 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 6 | 2020 | 60 | 0.740 |
Why?
| | Cardiomyopathies | 5 | 2025 | 335 | 0.700 |
Why?
| | Filamins | 4 | 2025 | 28 | 0.680 |
Why?
| | Connectin | 8 | 2026 | 42 | 0.670 |
Why?
| | Ventricular Function, Left | 6 | 2025 | 522 | 0.640 |
Why?
| | Death, Sudden, Cardiac | 7 | 2025 | 196 | 0.630 |
Why?
| | Phenotype | 17 | 2025 | 3199 | 0.500 |
Why?
| | Ventricular Remodeling | 3 | 2026 | 275 | 0.430 |
Why?
| | Genes, BRCA1 | 2 | 2005 | 45 | 0.420 |
Why?
| | Myocardium | 6 | 2026 | 949 | 0.410 |
Why?
| | Heart Failure | 8 | 2026 | 2181 | 0.410 |
Why?
| | Glycogen Storage Disease Type IIb | 3 | 2025 | 27 | 0.390 |
Why?
| | Electrocardiography | 6 | 2025 | 639 | 0.390 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2025 | 215 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 9 | 2026 | 2411 | 0.320 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 6 | 2016 | 93 | 0.310 |
Why?
| | Stroke Volume | 7 | 2025 | 617 | 0.290 |
Why?
| | RNA-Binding Proteins | 2 | 2026 | 468 | 0.290 |
Why?
| | Heart Ventricles | 4 | 2025 | 754 | 0.290 |
Why?
| | Receptors, Nicotinic | 4 | 2012 | 326 | 0.280 |
Why?
| | Founder Effect | 2 | 2005 | 13 | 0.280 |
Why?
| | Genetic Testing | 8 | 2025 | 479 | 0.270 |
Why?
| | Sequence Deletion | 3 | 2014 | 194 | 0.260 |
Why?
| | Myocytes, Cardiac | 4 | 2026 | 550 | 0.260 |
Why?
| | Mutation | 10 | 2020 | 4132 | 0.240 |
Why?
| | Iodide Peroxidase | 1 | 2026 | 34 | 0.240 |
Why?
| | Middle Aged | 28 | 2026 | 35939 | 0.230 |
Why?
| | Gene Expression Profiling | 2 | 2026 | 1829 | 0.230 |
Why?
| | DNA Mutational Analysis | 7 | 2018 | 408 | 0.230 |
Why?
| | Genetic Diseases, Inborn | 1 | 2025 | 44 | 0.230 |
Why?
| | Genetic Variation | 4 | 2021 | 991 | 0.220 |
Why?
| | Jews | 1 | 2005 | 19 | 0.220 |
Why?
| | Nanotubes, Carbon | 1 | 2025 | 48 | 0.220 |
Why?
| | Female | 43 | 2026 | 78217 | 0.220 |
Why?
| | Rare Diseases | 1 | 2025 | 113 | 0.220 |
Why?
| | RNA Splicing | 1 | 2026 | 286 | 0.210 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2025 | 120 | 0.210 |
Why?
| | Male | 39 | 2026 | 72189 | 0.210 |
Why?
| | Quantitative Trait Loci | 1 | 2026 | 384 | 0.210 |
Why?
| | Prognosis | 8 | 2025 | 4253 | 0.200 |
Why?
| | Muscle Proteins | 3 | 2025 | 248 | 0.200 |
Why?
| | Mutation, Missense | 3 | 2015 | 342 | 0.200 |
Why?
| | Alternative Splicing | 1 | 2026 | 248 | 0.200 |
Why?
| | Precision Medicine | 2 | 2026 | 463 | 0.200 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 195 | 0.200 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2000 | 38 | 0.200 |
Why?
| | Humans | 53 | 2026 | 144859 | 0.190 |
Why?
| | Adult | 26 | 2026 | 40438 | 0.190 |
Why?
| | Heart Rate | 2 | 2025 | 847 | 0.190 |
Why?
| | Genotype | 6 | 2025 | 1841 | 0.190 |
Why?
| | Germ-Line Mutation | 1 | 2003 | 174 | 0.180 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2022 | 45 | 0.170 |
Why?
| | Breast Neoplasms | 2 | 2005 | 2517 | 0.170 |
Why?
| | Biocompatible Materials | 1 | 2025 | 436 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2026 | 2633 | 0.170 |
Why?
| | Tissue Engineering | 1 | 2025 | 446 | 0.160 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2016 | 145 | 0.160 |
Why?
| | Physical Chromosome Mapping | 1 | 2000 | 20 | 0.160 |
Why?
| | Chromosome Breakage | 1 | 2000 | 22 | 0.160 |
Why?
| | Cell Adhesion | 2 | 2018 | 457 | 0.160 |
Why?
| | Chromosome Inversion | 1 | 2000 | 19 | 0.160 |
Why?
| | Heart-Assist Devices | 1 | 2026 | 562 | 0.150 |
Why?
| | Pedigree | 8 | 2015 | 514 | 0.150 |
Why?
| | Protein Kinases | 2 | 2012 | 315 | 0.150 |
Why?
| | Intellectual Disability | 1 | 2021 | 176 | 0.150 |
Why?
| | Ankyrins | 1 | 2019 | 12 | 0.150 |
Why?
| | Echocardiography | 4 | 2025 | 642 | 0.150 |
Why?
| | Mice, Inbred C3H | 3 | 2016 | 251 | 0.150 |
Why?
| | Recombination, Genetic | 1 | 2000 | 203 | 0.140 |
Why?
| | Cardiovascular Agents | 2 | 2025 | 158 | 0.140 |
Why?
| | Myocardial Infarction | 1 | 2026 | 1084 | 0.140 |
Why?
| | Hippocampus | 2 | 2016 | 969 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2000 | 196 | 0.140 |
Why?
| | Hydrogels | 1 | 2025 | 705 | 0.130 |
Why?
| | Retrospective Studies | 10 | 2026 | 16937 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2025 | 439 | 0.130 |
Why?
| | Disease Management | 3 | 2021 | 639 | 0.130 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 212 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2003 | 595 | 0.130 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 4 | 0.130 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 27 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 273 | 0.130 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 278 | 0.130 |
Why?
| | Internationality | 1 | 2017 | 154 | 0.130 |
Why?
| | Marfan Syndrome | 1 | 2017 | 46 | 0.130 |
Why?
| | Aged | 11 | 2026 | 25822 | 0.120 |
Why?
| | Transcriptome | 2 | 2020 | 1060 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2021 | 434 | 0.120 |
Why?
| | Lamin Type A | 3 | 2025 | 51 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 543 | 0.120 |
Why?
| | Genetic Association Studies | 3 | 2025 | 376 | 0.110 |
Why?
| | Registries | 6 | 2025 | 2253 | 0.110 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2017 | 139 | 0.110 |
Why?
| | Desmosomes | 1 | 2014 | 22 | 0.110 |
Why?
| | Spain | 2 | 2005 | 49 | 0.110 |
Why?
| | Receptors, Adrenergic | 1 | 2014 | 20 | 0.110 |
Why?
| | Base Sequence | 5 | 2014 | 2188 | 0.100 |
Why?
| | Long-Term Potentiation | 1 | 2016 | 200 | 0.100 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 50 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 188 | 0.100 |
Why?
| | Exons | 3 | 2025 | 358 | 0.100 |
Why?
| | Cohort Studies | 5 | 2026 | 5898 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2026 | 2186 | 0.100 |
Why?
| | Pharmacogenetics | 1 | 2014 | 173 | 0.090 |
Why?
| | Heterozygote | 3 | 2025 | 316 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 6067 | 0.090 |
Why?
| | Risk Assessment | 4 | 2025 | 3580 | 0.090 |
Why?
| | Mice, Knockout | 4 | 2026 | 3147 | 0.090 |
Why?
| | Genes, Duplicate | 1 | 2011 | 4 | 0.090 |
Why?
| | Schizophrenia | 3 | 2012 | 435 | 0.090 |
Why?
| | Colorado | 4 | 2017 | 4606 | 0.090 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2025 | 62 | 0.080 |
Why?
| | Neural Inhibition | 1 | 2012 | 178 | 0.080 |
Why?
| | Animals | 13 | 2026 | 38331 | 0.080 |
Why?
| | Organ Specificity | 2 | 2026 | 315 | 0.080 |
Why?
| | Age of Onset | 2 | 2025 | 544 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 960 | 0.070 |
Why?
| | Molecular Sequence Data | 5 | 2014 | 2914 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2025 | 559 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 97 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1430 | 0.070 |
Why?
| | Time Factors | 4 | 2025 | 7107 | 0.070 |
Why?
| | Desmin | 1 | 2007 | 24 | 0.060 |
Why?
| | Biomarkers | 1 | 2018 | 4279 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2025 | 829 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1257 | 0.060 |
Why?
| | Cloning, Molecular | 3 | 2011 | 543 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 14033 | 0.060 |
Why?
| | Mice | 6 | 2026 | 18549 | 0.060 |
Why?
| | DNA Methylation | 1 | 2011 | 681 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2026 | 54 | 0.060 |
Why?
| | Neurons | 1 | 2015 | 1645 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2026 | 67 | 0.060 |
Why?
| | Syndrome | 2 | 2011 | 377 | 0.060 |
Why?
| | Risk Factors | 4 | 2025 | 10672 | 0.060 |
Why?
| | Ventricular Myosins | 1 | 2005 | 37 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5350 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 36 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1506 | 0.050 |
Why?
| | Injections | 1 | 2025 | 199 | 0.050 |
Why?
| | Introns | 1 | 2025 | 252 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 184 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 145 | 0.050 |
Why?
| | Myosin Heavy Chains | 1 | 2005 | 186 | 0.050 |
Why?
| | Aortic Diseases | 1 | 2025 | 123 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 55 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 452 | 0.050 |
Why?
| | Disease-Free Survival | 2 | 2015 | 772 | 0.050 |
Why?
| | Particle Size | 1 | 2025 | 409 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2025 | 225 | 0.050 |
Why?
| | Materials Testing | 1 | 2025 | 359 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2003 | 33 | 0.050 |
Why?
| | Karyotyping | 2 | 2000 | 107 | 0.050 |
Why?
| | Haplotypes | 1 | 2005 | 491 | 0.050 |
Why?
| | Disease Progression | 2 | 2025 | 2881 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2026 | 1461 | 0.050 |
Why?
| | Genome, Human | 1 | 2025 | 429 | 0.050 |
Why?
| | DNA, Neoplasm | 1 | 2003 | 166 | 0.050 |
Why?
| | Chromosome Mapping | 5 | 2009 | 513 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2019 | 5809 | 0.050 |
Why?
| | Chromosomes, Human, Pair 15 | 2 | 2015 | 53 | 0.050 |
Why?
| | Brain | 1 | 2015 | 2934 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 177 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 276 | 0.040 |
Why?
| | Temperature | 1 | 2025 | 684 | 0.040 |
Why?
| | Recovery of Function | 1 | 2026 | 702 | 0.040 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 2 | 2014 | 32 | 0.040 |
Why?
| | Microarray Analysis | 1 | 2021 | 118 | 0.040 |
Why?
| | Cell Line | 3 | 2009 | 2911 | 0.040 |
Why?
| | Chromosomes | 1 | 2021 | 108 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2021 | 165 | 0.040 |
Why?
| | Cricetinae | 2 | 2000 | 300 | 0.040 |
Why?
| | Adolescent | 6 | 2025 | 22396 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 186 | 0.040 |
Why?
| | Rats | 2 | 2026 | 5632 | 0.040 |
Why?
| | Terminal Repeat Sequences | 1 | 2000 | 18 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2018 | 3628 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2026 | 2538 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2000 | 127 | 0.040 |
Why?
| | Alu Elements | 1 | 2000 | 28 | 0.040 |
Why?
| | New Mexico | 1 | 2000 | 103 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2030 | 0.040 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2000 | 32 | 0.040 |
Why?
| | Atrial Fibrillation | 1 | 2025 | 519 | 0.040 |
Why?
| | Maleimides | 1 | 2019 | 21 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 199 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2020 | 2860 | 0.040 |
Why?
| | Transfection | 3 | 2011 | 952 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2005 | 1184 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2090 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 180 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 621 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11581 | 0.030 |
Why?
| | Alleles | 1 | 2021 | 883 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1267 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2020 | 530 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2021 | 542 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1495 | 0.030 |
Why?
| | Developmental Disabilities | 1 | 2021 | 295 | 0.030 |
Why?
| | Family Health | 2 | 2011 | 193 | 0.030 |
Why?
| | Child | 4 | 2025 | 22620 | 0.030 |
Why?
| | Family | 2 | 2014 | 693 | 0.030 |
Why?
| | Fibrosis | 1 | 2020 | 548 | 0.030 |
Why?
| | HeLa Cells | 2 | 2011 | 654 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2971 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 467 | 0.030 |
Why?
| | beta Catenin | 1 | 2019 | 254 | 0.030 |
Why?
| | Europe | 1 | 2018 | 412 | 0.030 |
Why?
| | Aneurysm, False | 1 | 2017 | 46 | 0.030 |
Why?
| | Neck | 1 | 2017 | 110 | 0.030 |
Why?
| | Heredity | 1 | 2015 | 12 | 0.030 |
Why?
| | Sensory Gating | 1 | 2016 | 44 | 0.030 |
Why?
| | Italy | 1 | 2015 | 114 | 0.030 |
Why?
| | Head | 1 | 2017 | 120 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 145 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 201 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 493 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4605 | 0.030 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1994 | 5 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 576 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2016 | 333 | 0.030 |
Why?
| | Prevalence | 2 | 2015 | 2830 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2011 | 274 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 485 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1994 | 116 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1993 | 38 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 1994 | 1058 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1734 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 322 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1058 | 0.020 |
Why?
| | Cause of Death | 1 | 2015 | 461 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2011 | 3633 | 0.020 |
Why?
| | Heart | 1 | 2017 | 635 | 0.020 |
Why?
| | Action Potentials | 1 | 2016 | 509 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1510 | 0.020 |
Why?
| | United States | 3 | 2018 | 15723 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2000 | 898 | 0.020 |
Why?
| | Genotyping Techniques | 1 | 2012 | 70 | 0.020 |
Why?
| | Mice, 129 Strain | 1 | 2012 | 87 | 0.020 |
Why?
| | Penetrance | 1 | 2011 | 29 | 0.020 |
Why?
| | Bungarotoxins | 1 | 2011 | 45 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2000 | 6406 | 0.020 |
Why?
| | Xenopus laevis | 1 | 2011 | 103 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 395 | 0.020 |
Why?
| | Allosteric Regulation | 1 | 2011 | 98 | 0.020 |
Why?
| | Isoxazoles | 1 | 2011 | 53 | 0.020 |
Why?
| | Electrophysiological Phenomena | 1 | 2011 | 60 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 173 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2098 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 685 | 0.020 |
Why?
| | Multigene Family | 1 | 2011 | 204 | 0.020 |
Why?
| | Phenylurea Compounds | 1 | 2011 | 112 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2103 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2011 | 289 | 0.020 |
Why?
| | Point Mutation | 1 | 2011 | 245 | 0.020 |
Why?
| | Oocytes | 1 | 2011 | 177 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 674 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 992 | 0.020 |
Why?
| | Autistic Disorder | 1 | 2012 | 217 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 733 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2009 | 249 | 0.020 |
Why?
| | RNA | 2 | 2011 | 941 | 0.020 |
Why?
| | Child, Preschool | 2 | 2000 | 11740 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2149 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2940 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2007 | 32 | 0.020 |
Why?
| | Epilepsy | 1 | 2012 | 376 | 0.020 |
Why?
| | Genes, Dominant | 1 | 2007 | 100 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 687 | 0.020 |
Why?
| | Cognition | 1 | 2015 | 1262 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2012 | 790 | 0.010 |
Why?
| | Signal Transduction | 1 | 2020 | 5277 | 0.010 |
Why?
| | Mental Disorders | 1 | 2015 | 1137 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2007 | 423 | 0.010 |
Why?
| | Prospective Studies | 1 | 2018 | 7947 | 0.010 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 75 | 0.010 |
Why?
| | Sarcomeres | 1 | 2005 | 99 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2276 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2005 | 243 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2005 | 404 | 0.010 |
Why?
| | Smoking | 1 | 2011 | 1557 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 454 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 858 | 0.010 |
Why?
| | DNA Primers | 2 | 1994 | 517 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 374 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1517 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2007 | 4177 | 0.010 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1981 | 3 | 0.010 |
Why?
| | Carbon-Nitrogen Ligases | 1 | 1981 | 5 | 0.010 |
Why?
| | Ligases | 1 | 1981 | 29 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2005 | 1810 | 0.010 |
Why?
| | Muridae | 1 | 1994 | 6 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 1994 | 24 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1994 | 126 | 0.010 |
Why?
| | Cosmids | 1 | 1993 | 8 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1993 | 81 | 0.010 |
Why?
| | Genetic Markers | 1 | 1994 | 338 | 0.010 |
Why?
| | Infant | 1 | 2007 | 9987 | 0.010 |
Why?
| | Genome | 1 | 1994 | 304 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1981 | 49 | 0.000 |
Why?
| | Genetic Complementation Test | 1 | 1981 | 67 | 0.000 |
Why?
| | Cell Fusion | 1 | 1981 | 49 | 0.000 |
Why?
| | Cricetulus | 1 | 1981 | 116 | 0.000 |
Why?
| | Purines | 1 | 1981 | 188 | 0.000 |
Why?
| | Ovary | 1 | 1981 | 227 | 0.000 |
Why?
| | Lymphocytes | 1 | 1981 | 396 | 0.000 |
Why?
| | Fibroblasts | 1 | 1981 | 1042 | 0.000 |
Why?
|
|
Graw's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|